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Atherosclerosis, a chronic inflammatory disorder of the walls of arteries, causes more deaths worldwide 
than any other disease. Cytokines, which are present at high levels in atherosclerotic plaques, play 
important roles in regulating the initiation and the progression of the disease. Previous studies using 
animal and cell culture model systems revealed protective, anti-atherogenic effects of the cytokine 
interleukin-33 (IL-33). The action of this cytokine involves both the induction and suppression of 
expression of many genes. Unfortunately, the signaling pathways that are responsible for the inhibition 
of gene expression by this cytokine are poorly understood. Further studies are required given the 
important roles of genes whose expression is inhibited by IL-33 in key cellular processes associated with 
atherosclerosis such as monocyte recruitment, foam cell formation and lipoprotein metabolism. We 
have investigated here the roles of various known IL-33 activated signaling pathways in such inhibitory 
actions using RNA interference-mediated knockdown assays and monocyte chemotactic protein-1 and 
intercellular adhesion molecule-1 as model genes. Key roles were identified for extracellular signal-
regulated kinase-1/2, p38α kinase, c-Jun N-terminal kinase-1/2, phosphoinositide 3-kinase-γ, and p50 
and p65 nuclear factor-κB in such inhibitory action of IL-33. These studies provide new insights on the 
signaling pathways through which IL-33 inhibits the macrophage expression of key atherosclerosis-
associated genes.
Atherosclerosis, a major underlying cause of coronary heart disease (CHD), is associated with inflamma-
tion of the arterial wall1,2. The disease is initiated by endothelial cell dysfunction or activation in response to 
pro-inflammatory stimuli, such as modified low-density lipoproteins (LDL). This results in increased secretion of 
chemokines [e.g. monocyte chemotactic protein-1 (MCP-1)] by the endothelial cells along with the expression of 
cell surface adhesion molecules [e.g. intercellular adhesion molecule-1 (ICAM-1)], which together facilitate the 
recruitment, attachment and infiltration of circulating leukocytes into the subendothelial space1,2. Early athero-
sclerotic lesions are characterized by the accumulation of macrophages1–3. Lesion-resident macrophages take up 
LDL and oxidized LDL (oxLDL) through several processes, including macropinocytosis, phagocytosis and scav-
enger receptors-mediated endocytosis, thereby leading to their transformation into lipid-laden foam cells1,2,4,5. 
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Furthermore, macrophages also serve as major sources of pro- and anti-inflammatory cytokines, which play cru-
cial roles in the innate and adaptive immune responses associated with atherosclerosis3,4,6,7. Cytokines participate 
in all stages of the disease, including endothelial cell dysfunction, foam cell formation and secretion of matrix 
metalloproteinases involved in the degradation of extracellular matrix components7,8.
Many recent studies have demonstrated a protective anti-atherogenic role for the more recently identi-
fied cytokine interleukin (IL)-332,8. Thus, reduced atherosclerosis was seen in the Apolipoprotein E deficient 
(ApoE−/−) mouse model system following administration of recombinant IL-339. Several mechanisms were iden-
tified for the anti-atherogenic effects of IL-33: phenotypic switch from T helper (Th)1 to Th2 cells, increased 
production of anti-inflammatory cytokines IL-4 and IL-13, and the secretion of oxLDL antibodies9. Conversely, 
inhibition of IL-33 actions by the administration of a soluble decoy receptor promoted atherosclerosis develop-
ment in this model system9. In addition, research in our laboratory demonstrated that IL-33 decreased foam cell 
formation in vivo in such ApoE−/− mice10. Further studies on macrophages, which constitutively express the ST2 
receptor10–13, in vitro revealed the potential mechanisms for the anti-foam cell action of IL-33. Thus, IL-33 caused 
a reduction in the uptake of modified LDL together with the expression of scavenger receptors SR-A, SR-B1 and 
CD36 (involved in the cellular uptake of modified LDL) and acyl-coA cholesterol acyltransferase-1 (involved in 
intracellular esterification of cholesterol)10. In contrast, cholesterol efflux from foam cells was stimulated by IL-33, 
and associated with up-regulated expression of cholesterol efflux transporters; ATP-binding cassette transporter 
(ABC)A1 and ABCG110. The requirement of the ST2 receptor in the anti-foam cell actions of IL-33 together 
with associated changes in gene expression was confirmed by the use of bone marrow-derived macrophages 
(BMDM) from mice deficient in this receptor10. Subsequent studies have also confirmed the requirement of the 
ST2 receptor in the IL-33-mediated regulation of expression of other genes in human macrophages together 
with its anti-foam cell action11,13. IL-33 also inhibited macropinocytosis5, which contributes to the disease via the 
macrophage uptake of LDL particles1.
Both the up- and down-regulation of gene expression is associated with the cellular actions of IL-33. Several 
signaling pathways are activated by IL-33 in various cell types, including nuclear factor-κB (NF-κB), phospho-
inositide 3-kinase (PI3K) and mitogen activated protein kinases (MAPK)14–21. Unfortunately, in contrast to acti-
vation, the signaling pathways involved in the suppression of gene expression by IL-33 are poorly understood 
mainly due to limited previous research and hence formed the focus of our current study on human macrophages 
using MCP-1 and ICAM-1 as model genes. We show key roles for extracellular signal-regulated kinase (ERK)-1/2, 
p38α MAPK, c-Jun N-terminal kinase (JNK)-1/2, PI3K-γ, and p50 and p65 NF-κB.
Results
The expression of MCP-1 and ICAM-1 genes in human macrophages is inhibited by IL-33. We 
have shown previously that IL-33 attenuates macrophage foam cell formation both in vitro and in vivo10. The 
action of IL-33 was conserved between human THP-1 macrophages, which have been used in numerous studies 
on macrophages in relation to atherosclerosis22, and primary cultures of human monocyte-derived macrophages 
(HMDM) and mouse BMDM, and also extended to the in vivo context10. These studies therefore validate the use 
of THP-1 macrophages and/or HMDM and/or BMDM for the investigation of IL-33 actions in relation to ather-
osclerosis10 as employed previously with other agents e.g.23–25.
We have previously shown that the expression of scavenger receptors SR-A1, SR-B1 and CD36 was attenuated 
by IL-33 in both THP-1 macrophages and HMDM10. Preliminary results showed that such an inhibitory action 
of IL-33 extended to other key atherosclerosis-associated genes: lipoprotein lipase, a key enzyme involved in 
the control of lipoprotein metabolism26; the adhesion protein ICAM-1, and the chemokines MCP-1, interferon 
gamma-induced protein-10 and macrophage inflammatory protein-1β in THP-1 macrophages (data not shown). 
Because of the crucial roles of MCP-1 and ICAM-1 in facilitating the recruitment and attachment of circulating 
leukocytes during the disease state1,7,8, subsequent studies focused on these atherosclerotic markers with a view of 
identifying the signaling pathways involved in the suppression of gene expression by the cytokine. Experiments 
were first carried out on primary cultures of HMDM to confirm that the inhibitory action of IL-33 on MCP-1 and 
ICAM-1 expression was not because of the use of the THP-1 cell line. As shown in Fig. 1, IL-33 significantly inhib-
ited MCP-1 and ICAM-1 mRNA expression in HMDM (p = 0.040 and p = 0.011, respectively). The concentration 
of IL-33 used in these experiments (25 ng/ml) was within the physiological range (can reach up to 40 ng/ml)10.
Macrophages, including those derived from THP-1 monocytes, express the ST2 receptor11,12,15,21. For exam-
ple, our previous studies showed that the ST2 receptor mRNA was expressed in both THP-1 macrophages and 
HMDM10 and this was extended in the current study to the protein level (Supplementary Fig. 1). Our previous 
research using BMDM from ST2 deficient mice showed that this receptor was required for all the IL-33-mediated 
changes in cellular processes and gene expression that we analyzed (e.g. inhibition of modified LDL uptake, cel-
lular levels of total cholesterol and cholesteryl esters and the expression of SR-A1, CD36, SR-B1, ADAMTS-1 and 
ADAMTS-4; induction of cholesterol efflux and expression of ABCA1, ABCG1 and ApoE)10,13. Nevertheless, a 
neutralizing antibody with appropriate isotype control was used to investigate the requirement of the ST2 recep-
tor for the changes in the expression of the MCP-1 and ICAM-1 genes by IL-33. Because of technical issues (i.e. 
compromised IL-33 response in the presence of isotype control antibody for MCP-1), conclusions could only be 
made for ICAM-1. The inhibition of ICAM-1 expression by IL-33 seen in THP-1 macrophages pre-incubated 
with the isotype control antibody was attenuated when the cells were instead pre-treated with anti-ST2 neutraliz-
ing antibody (Supplementary Fig. 2A). Despite the conservation of responses between THP-1 macrophages and 
HMDM, experiments were repeated in the latter cellular system. Although the decrease in ICAM-1 expression 
by IL-33 was not significant in HMDM pre-treated with the isotype control antibody, such a reduction was not 
seen following pre-treatment of the cells with ST2 neutralizing antibody (Supplementary Fig. 2B). This adds to 
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our previously published studies that shows that the ST2 receptor is required for all the IL-33-mediated changes 
in cellular processes that we have investigated10,13.
MAP kinases, NF-κB and PI3K-γ are involved in the IL-33-mediated down-regulation of MCP-1 
and ICAM-1 expression. IL-33 activates multiple signaling pathways in several cellular systems14–19, includ-
ing PI3K, NF-κB and the three MAPK cascades (ERK, JNK and p38), though very few studies have addressed 
their roles in relation to inhibition of gene expression by the cytokine. The requirement of key components in the 
MAPK, NF-κB and PI3Kγ signaling pathways in the inhibition of MCP-1 and ICAM-1 expression by IL-33 was 
therefore investigated by knockdown assays in THP-1 macrophages. Knockdown of targets was achieved using 
adenoviral encoding small hairpin RNAs (shRNAs) and/or small interfering RNAs (siRNAs).
The use of shRNA targeting the major p38 isoform, p38α, produced a significant reduction in p38α mRNA 
and protein levels in vehicle and IL-33 treated cells respectively [55% (p < 0.001) and 50% (p < 0.001) respec-
tively at mRNA expression and 86% (p < 0.001) and 72% (p = 0.002) respectively at the protein level] (Fig. 2A,B). 
RT-qPCR showed that the significant decrease in MCP-1 and ICAM-1 expression by IL-33 seen in cells trans-
fected with the scramble control (p = 0.008 and p = 0.006, respectively) was attenuated following knockdown of 
p38α (Fig. 2C,D), thereby indicating a requirement for this kinase in the inhibitory action of this cytokine.
The involvement of the MAPKs JNK1 and JNK2 was investigated by transfection of the cells with siRNAs 
against JNK-1 and -2. The expression of both isoforms was knocked down together because of the existence 
of extensive functional redundancy in numerous responses27. The expression of JNK1 mRNA was significantly 
decreased by 50% in vehicle-treated cells (p = 0.007) with a non-significant reduction (31%; p = 0.130) observed 
in those stimulated with IL-33 (Fig. 3A). Similarly, JNK2 mRNA expression was significantly decreased by 65% 
and 31% in vehicle- and IL-33-treated cells respectively (p < 0.001 and p = 0.001 respectively) (Fig. 3B). Western 
blot analysis confirmed the knockdown at the protein level (Fig. 3C). The significant reduction in MCP-1 and 
ICAM-1 expression by IL-33 observed in cells transfected with the negative control (p = 0.006 and p = 0.009 
respectively) was attenuated following knockdown of JNK1/2 (Fig. 3D,E), with a significant increase in expression 
seen for MCP-1 (p = 0.016), thereby indicating a requirement for this kinase in the action of IL-33.
For the ERK pathway, the expression was initially knocked down using adenoviral-encoding shRNA against 
individual isoforms. Because of only a slight reduction of ERK2 at the protein level in IL-33-treated cells (~22%; 
Figure 1. The effect of IL-33 on MCP-1 and ICAM-1 expression in primary macrophages. RT-qPCR for MCP-1 
(A) and ICAM-1 (B) was carried out using cDNA against RNA from primary HMDMs that were incubated 
for 12 h in the presence of vehicle (−) or 25 ng/ml of IL-33 (+). The mRNA levels were calculated using the 
comparative Ct method and normalized to the housekeeping gene, GAPDH, with values from vehicle-treated 
control cells given an arbitrary value of 1. Data represents mean ± SEM from four independent experiments. 
Statistical analysis was carried out using an unpaired Student’s t test (*p ≤ 0.05).
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data not shown), siRNA-mediated knockdown was carried out for this isoform. The data for ERK1 shRNA 
and ERK2 siRNA are presented in Fig. 4. The knockdown of ERK1 mRNA was 78% and 86% in vehicle- and 
IL-33-treated cells respectively (p < 0.001 in both cases) and for ERK2 of 40% and 26% respectively (p = 0.001 
Figure 2. p38α is required for the IL-33-mediated inhibition of MCP-1 and ICAM-1 expression in human 
macrophages. Knockdown using adenovirus-encoding shRNA against p38α (p38) or scramble (Scr) sequence 
was carried out as Materials and Methods. THP-1 macrophages were then incubated for 12 h in the presence 
of vehicle (−) or 25 ng/ml IL-33 (+). The mRNA expression of p38α (A), MCP-1 (C) and ICAM-1 (D) was 
analyzed by RT-qPCR. Data represents mean ± SEM from six independent experiments. The expression of p38 
protein levels was determined by Western blot analysis using β-actin as control (B). A representative image with 
signal from immunoreactive p38 or β-actin is shown (see Supplementary Fig. 4 for corresponding full-length 
image) with the histogram below it indicating p38 protein expression (mean ± SEM) normalized to β-actin 
from three independent experiments. The knockdown of p38α in vehicle- or IL-33 treated cells was determined 
in relation to the scramble control, which was arbitrarily assigned as 1 (A,B). The IL-33-mediated changes in 
MCP-1 and ICAM-1 expression in the scramble control was compared to that following knockdown of p38α 
(C,D) with values from cells infected with scramble shRNA or p38α shRNA and then treated with vehicle alone 
given an arbitrary value of 1. Statistical analysis was carried out using an unpaired Student’s t-test (A–C) or Man 
Whitney U test (D) (**p ≤ 0.01, ***p ≤ 0.001).
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and 0.168 respectively) (Fig. 4A,B). The knockdown was specific to the isoform (Supplementary Fig. 3A,B). Thus, 
the expression of ERK1 was not reduced following knockdown of ERK2 and vice versa the expression of ERK2 
was not decreased following knockdown of ERK1. Western blot analysis revealed that the knockdown of ERK1 
Figure 3. JNK1/2 is required for the IL-33-mediated inhibition of MCP-1 and ICAM-1 expression in human 
macrophages. Knockdown using siRNA against JNK1/2 (JNK) or negative control sequence (Neg) was carried 
out as Materials and Methods. THP-1 macrophages were then incubated for 12 h in the presence of vehicle 
(−) or 25 ng/ml IL-33 (+). The mRNA expression of JNK1 (A), JNK2 (B), MCP-1 (D) and ICAM-1 (E) was 
analyzed by RT-qPCR. Data represents mean ± SEM from five independent experiments. The knockdown 
of JNK1 (A) or JNK2 (B) in vehicle- or IL-33 treated cells was determined in relation to the negative control, 
which was arbitrarily assigned as 1 (A,B). The IL-33-mediated changes in MCP-1 and ICAM-1 expression in the 
negative control was compared to that following knockdown of JNK1/2 (D,E) with values from cells transfected 
with negative control siRNA or JNK1/2 siRNA and then treated with vehicle alone given an arbitrary value of 1. 
Statistical analysis was carried out using an unpaired Student’s t-test (*p ≤ 0.05; **p ≤ 0.01, ***p ≤ 0.001). The 
expression of JNK1/2 protein levels was determined by Western blot analysis using β-actin as a control (C). A 
representative image from two independent experiments with signals from immunoreactive JNK1/2 or β-actin 
is shown (see Supplementary Fig. 5 for corresponding full-length image).
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protein was 56% and 48% in vehicle- and IL-33-treated cells respectively (p = 0.009 and p = 0.018 respectively) 
and for ERK2 of 68% and 64% (p = 0.001 and p = 0.031 respectively) (Fig. 4C,D). Thus, a significant reduction 
of both ERK1 and -2 proteins was obtained in vehicle- and IL-33-treated cells. Analysis of data from multiple 
Figure 4. ERK1/2 is required for the IL-33-mediated inhibition of MCP-1 and ICAM-1 expression in human 
macrophages. Knockdown using adenovirus encoding shRNA against ERK1 or scramble (Scr) sequence or 
siRNA against ERK2 or negative control sequence (Neg) was carried out as Materials and Methods. THP-1 
macrophages were then incubated for 12 h in the presence of vehicle (−) or 25 ng/ml IL-33 (+). Expression of 
mRNA for ERK1 (A), ERK2 (B), MCP-1 (E,G) and ICAM-1 (F,H) was analyzed by RT-qPCR. Data represents 
mean ± SEM from three to five independent experiments. The expression of ERK1/2 protein levels was 
determined by Western blot analysis using β-actin as a control (C,D). A representative image with signal from 
immunoreactive ERK1/2 or β-actin is shown (see Supplementary Figs 6 and 7 for corresponding full-length 
image for panels (C,D) respectively) with the histogram below it indicating ERK-1 or -2 protein expression 
normalized to β-actin from three to four independent experiments. The knockdown of ERK1/2 in vehicle- or 
IL-33 treated cells was determined in relation to the scramble/negative control, which was arbitrarily assigned as 
1 (A–D). The IL-33-mediated changes in MCP-1 and ICAM-1 expression in the scramble/negative control was 
compared to that following knockdown of ERK1/2 (E–H) with values from cells treated with scramble/negative 
control or ERK1 shRNA/ERK2 siRNA and then incubated with vehicle alone given an arbitrary value of 1. 
Statistical analysis was carried out using an unpaired Student’s t-test (A,E,F) or Man Whitney U test (B–D,G,H) 
(*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
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experiments revealed that the knockdown was also specific at the protein level (Supplementary Fig. 3C,D). The 
significant IL-33-mediated decrease in MCP-1 and ICAM-1 mRNA expression (p = 0.031 and p = 0.005 respec-
tively for ERK1 shRNA, and p = 0.021 and p = 0.004 respectively for ERK2 siRNA) was attenuated following 
knockdown of ERK-1 or -2 (Fig. 4E–H). In the case of ERK1 knockdown, the reduction in MCP-1 expression by 
IL-33 was reversed with significantly increased levels being observed (Fig. 4E; p = 0.018). Similarly, in the case of 
ERK2 knockdown, the IL-33-mediated reduction in ICAM-1 expression was reversed with significantly increased 
levels also being observed (Fig. 4H; p = 0.039).
p50 and p65 are the major NF-κB family members implicated in cytokine signaling and the control of the 
inflammatory response2. Their expression was therefore knocked down using siRNA. In the case of p50, a signif-
icant decrease in mRNA expression of 55% and 32% was observed in vehicle- and IL-33-treated cells respectively 
(p < 0.001 and p = 0.022 respectively) (Fig. 5A). For p65, the decrease was 51% and 45% respectively (p < 0.001 
in both cases) (Fig. 5B). Western blot analysis confirmed the knockdown at the protein level (Fig. 5C,D). Thus, 
the knockdown of p50 was 38% and 45% in vehicle- and IL-33-treated cells respectively (p = 0.003 and p < 0.001 
respectively) and 56% and 38% respectively in the case of the p65 isoform (p < 0.001 and p = 0.001 respectively) 
Figure 5. Both p50 and p65 NFκB are required for the IL-33-mediated inhibition of MCP-1 expression in 
human macrophages. Knockdown using siRNA against p50/p65 NFκB or negative control sequence (Neg) 
was carried out as Materials and Methods. THP-1 macrophages were then incubated for 12 h in the presence 
of vehicle (−) or 25 ng/ml IL-33 (+). Expression of mRNA for p50 (A) or p65 (B) or MCP-1 (E) was analyzed 
by RT-qPCR. Data represents mean ± SEM from three independent experiments. The expression of p50 or p65 
protein levels was determined by Western blot analysis using β-actin as a control. A representative image with 
signal from immunoreactive p50, p65 or β-actin is shown (see Supplementary Figs 8 and 9 for corresponding 
full-length image for panels (C,D) respectively) with the histogram below it indicating p50 or p65 protein 
expression normalized to β-actin. The knockdown of p50/p65 in vehicle- or IL-33 treated cells was determined 
in relation to the negative control, which was arbitrarily assigned as 1 (A–D). The IL-33-mediated changes in 
MCP-1 expression in the negative control was compared to that following knockdown of p50/p65 (E) with 
values from cells transfected with negative control siRNA or p50/p65 siRNA and then treated with vehicle alone 
given an arbitrary value of 1. Statistical analysis was carried out using an unpaired Student’s t test (*p ≤ 0.05, 
**p ≤ 0.01, ***p ≤ 0.001).
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(Fig. 5C,D). In the case of MCP-1, the significant IL-33-mediated reduction of mRNA expression observed in 
cells transfected with negative control siRNA (p < 0.001) was attenuated following knockdown of both NF-κB 
isoforms (Fig. 5D). Conclusions could not be made for ICAM-1 expression as none of the changes were signifi-
cant, including in cells transfected with negative siRNA (data not shown).
The PI3K family member, PI3K-γ, plays an important role in atherosclerosis2. Its involvement was therefore 
investigated by knockdown using adenoviral-encoding shRNA. The knockdown of PI3K-γ mRNA was 60% and 
61% respectively in vehicle- and IL-33 treated cells respectively (p < 0.001 in both cases) (Fig. 6A). The signifi-
cant reduction in MCP-1 and ICAM-1 expression by IL-33 in cells infected with adenovirus encoding scramble 
shRNA (p = 0.019 and p = 0.002 respectively) was attenuated following knockdown of PI3K-γ (Fig. 6B,C).
Discussion
IL-33 is a more recently identified IL-1 family member with important functions in regulating infection, inflam-
mation and cancer21. The actions of this cytokine in such disorders are mediated via a range of immune cells, 
including macrophages21. We have previously shown inhibition of macrophage foam cell formation in vitro and 
in vivo by IL-3310. In addition, we demonstrated the requirement of the ST2 receptor for its effect on cholesterol 
homeostasis and the regulation of gene expression in macrophages in vitro10. We show here that IL-33 attenuates 
the expression of MCP-1 and ICAM-1, two major pro-atherogenic genes, in human macrophages and identify the 
roles of key signaling pathways activated by this cytokine in such regulation using knockdown assays.
An important role for IL-33 in atherosclerosis was identified by studies in the ApoE deficient mouse model 
system9. The disease was attenuated by injection of IL-33 and exacerbated with the soluble ST2 receptor that 
prevents the cytokine from initiating cellular responses9. IL-33 increased the levels of several anti-atherogenic 
Figure 6. PI3Kγ is required for the IL-33-mediated inhibition of MCP-1 and ICAM-1 expression in human 
macrophages. Knockdown using adenovirus encoding shRNA against PI3Kγ or scramble (Scr) sequence 
was carried out as Materials and Methods. THP-1 macrophages were then incubated for 12 h in the presence 
of vehicle (−) or 25 ng/ml IL-33 (+). Expression of mRNA for PI3Kγ (A), MCP-1 (B) and ICAM-1 (C) 
was analyzed by RT-qPCR. Data represents mean ± SEM from three to six independent experiments. The 
knockdown of PI3Kγ in vehicle- or IL-33 treated cells was determined in relation to the scramble control, 
which was arbitrarily assigned as 1 (A). The IL-33-mediated changes in MCP-1 and ICAM-1 expression 
in the scramble control was compared to that following knockdown of PI3Kγ (B,C) with values from cells 
infected with scramble shRNA or PI3Kγ shRNA and then treated with vehicle alone given an arbitrary value 
of 1. Statistical analysis was carried out using an unpaired Student’s t test (A,C) or Mann Whitney U test (B) 
(*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
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cytokines such as IL-13, decreased the expression of some pro-atherogenic cytokines (e.g. interferon-γ), caused a 
Th1 to Th2 shift and increased the concentration of anti-oxLDL antibodies9. However, a recent study in ApoE−/− 
mice deficient in either IL-33 or its ST2 receptor failed to find any effect on atherosclerosis28. The precise reasons 
for the discrepancy are currently unclear but differences in the experimental design such as cholesterol levels in 
the high fat diet and duration of the feeding may have contributed28. In addition, not all the actions of IL-33 are 
anti-atherogenic; for example, Demyanets et al.29 first showed that IL-33 activates human endothelial cells and 
increases the expression of MCP-1 and adhesion molecules in these cells in vitro and in human atherosclerotic 
plaques ex vivo. Subsequently, Pollheimer et al.30 also demonstrated that the cytokine causes endothelial cell acti-
vation with stronger responses in nonquiescent cells.
Our studies reveal an anti-atherogenic role for IL-33, provide mechanistic insights into such an action and 
add to the beneficial effects reported in the prevention of obesity31. For example, IL-33 decreased the formation of 
macrophage foam cells in vitro and in vivo10. The cytokine attenuated the expression of several key genes involved 
in modified LDL uptake and intracellular cholesterol storage and simultaneously induced the expression of genes 
required for the intracellular transport of this sterol and its efflux out of foam cells10. We have also shown that 
the expression of a disintegrin and metalloproteinase with thrombospondin motifs-4 in human macrophages 
was inhibited by IL-3313, and recently it has been demonstrated that its deficiency in ApoE−/− mice attenuates 
atherosclerosis development and improves plaque stability32. The studies presented here show that IL-33 inhib-
its the expression of MCP-1 and ICAM-1 that have been demonstrated to play pro-atherogenic roles in mouse 
model systems2,8. Interestingly, IL-33 induces the expression of some of these genes in other cell types; for exam-
ple, ICAM-1 in human eosinophils33 and MCP-1 and ICAM-1 in human endothelial cells29,30. This implicates 
cell-type-specific actions of the cytokine that needs to be investigated further. However, the mechanisms are likely 
to be complex given that the promoter regions of MCP-1 and ICAM-1 genes contain binding sites for several tran-
scription factors (e.g. signal transducer and activator of transcription-1, -3, and -5; E26 transformation-specific; 
CCAAT/enhancer binding proteins; activator protein-1; specificity protein-1; farnesoid X receptor; peroxisome 
proliferator-activated receptors etc), many of which have been shown to be functionally important34–43. All these 
transcription factors also belong to large families, with both activators and repressors, and additional complex-
ity created by large numbers of post-translational modifications, interactions between them or even with other 
proteins, and epigenetic regulation36,38–40. For example, NF-κB, which is known to stimulate MCP-1 and ICAM-1 
expression29,36,40, consists of five members that can also inhibit gene transcription with additional complexity 
created by interactions with numerous other transcription factors/proteins, post-translational modifications and 
epigenetic regulation that also produces suppression of gene expression44–52. It is therefore not surprising that 
experiments in mouse models have not always demonstrated pro-atherogenic roles for the different members2.
IL-33 is known to activate several signal transduction pathways such as NF-κB, MAPK and PI3K21. Many 
studies have determined the signaling pathways underlying IL-33 actions with some cell- and gene-specific 
responses being identified16–20,53. For example, IL-33 activates p38 MAPK in lung endothelial cells but not in 
epithelial cells20. The majority of previous research has studied the IL-33-mediated stimulation of gene expression 
or cellular responses. For instance, IL-33 has been shown to promote ovarian cancer cell growth and metastasis 
via ERK and JNK signaling pathways54. Unfortunately, the signaling pathways underlying the inhibitory actions 
of IL-33 are not well understood. Such inhibitory actions extend to key processes such as macrophage foam cell 
formation and immune cell recruitment to atherosclerotic plaques9,10, decidual natural killer cell cytotoxicity in 
early human pregnancy55 and cardiac remodelling following myocardial infarction56. Using knockdown assays, 
we show here a requirement of NF-κB, PI3Kγ and MAPK cascades in the IL-33-mediated inhibition of two 
key pro-atherogenic genes, MCP-1 and ICAM-1 (Figs 2–6). Interestingly, these pathways are required for both 
the induction and suppression of gene expression by IL-33. Future studies should investigate how differential 
responses following activation of these signaling pathways are achieved. These are beyond the scope of current 
studies because of the immense complexity of IL-33 signaling. For example, data mining has revealed an inte-
grated pathway map of IL-33 and its receptor that consists of 681 proteins and 765 reactions57. The complexity can 
be gauged by the involvement of 9 transcriptional regulators, 2492 gene regulation events and 740 enzyme catal-
ysis events57. In addition, quantitative phosphoproteomic analysis has revealed IL-33-mediated changes in phos-
phorylation at 1050 sites in 672 proteins58. Activation of numerous such proteins together with protein-protein 
interactions may make a key contribution to such differential effects.
In conclusion, the studies presented here supports that IL-33 exerts anti-atherogenic actions. The data demon-
strates that the cytokine causes a novel decrease in the expression of MCP-1 and ICAM-1. In addition, key roles 
for ERK1/2, p38α, JNK1/2, NF-κB and PI3Kγ were identified in such an inhibitory action of the cytokine.
Materials and Methods
Reagents. Human THP-1 cell line was from Sigma-Aldrich and recombinant human IL-33 was supplied by 
Peprotech. Antibodies were from Cell Signaling Technology [anti-p44/p42 (ERK1/2) (9102), anti-p38 (9212), 
anti-JNK1/2 (9252), NF-κB p105/p50 (3035)], Santa Cruz Biotechnology [NF-κB p65 (sc-372), β-Actin (sc-
130656)] or Sigma-Aldrich [β-Actin (A2228)].
Cell culture. HMDMs were isolated from buffy coats supplied by the National Blood Service Wales, which 
were processed immediately following collection using the Ficoll-Hypaque purification method as previ-
ously described10,23,25. Informed consent for each donor was granted to the Welsh Blood Service for the use of 
human blood for non-transfusion purposes10,23,25. All methods were carried out in accordance with the relevant 
guidelines and regulation (all experimental protocols were approved by the School of Biosciences and Cardiff 
University)10,23,25. THP-1 and HMDM were cultured in RPMI1640 medium with stable glutamine containing 
10% (v/v) heat-inactivated foetal calf serum, penicillin (100 U/ml) and streptomycin (100 µg/ml) at 37 °C in a 
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humidified atmosphere containing 5% (v/v) CO26,13,23–25. THP-1 monocytes were differentiated into macrophages 
by incubation for 24 h with 0.16 µM of phorbol 12-myristate 13-acetate (PMA)6,13,23–25.
Real-time quantitative PCR (RT-qPCR). Isolation of RNA, reverse transcription and RT-qPCR of the 
resulting cDNA were carried out as described elsewhere6,10,25. The sequences of the primers used are given in 
Supplementary Table 1. The comparative ΔΔCt method was used to represent relative expression normalized to 
the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH)10,25.
Western blotting. Size-fractionation of equal amounts of protein was carried out by SDS-PAGE alongside 
comparative molecular weight size markers and subjected to Western blot analysis as described elsewhere6,10,23,25.
RNA interference. Knockdown assays were performed by transfections using validated siRNAs targeting 
human ERK2 (SI00300755), JNK1 (SI02758637), JNK2 (SI02222920), p50 (SI02654932) and p65 (SI00301672) 
from Qiagen. Negative control siRNA (AM4611) was purchased from Invitrogen. Stock solutions of lyophilized 
siRNA were prepared in nuclease-free water in accordance with the manufacturer’s instructions (Qiagen and 
Invitrogen).
siRNA transfections were performed in THP-1 monocytes before the addition of PMA for differentiation into 
macrophages in accordance to the manufacturer’s instructions (Polyplus Transfection) as described in previous 
studies6,13,25. The preparation of small hairpin RNA (shRNA)-encoding recombinant adenovirus that target ERK-
1, ERK-2, p38α or PI3Kγ has been previously described13,24. The adenovirus was then added at a multiplicity of 
infection of 100 based on previous optimisation studies24,25. The cells were left for 2.5 hours at 37 °C in a humid-
ified incubator containing 5% (v/v) CO2 before the addition of 0.16 µM PMA. Incubation of the cells at 37 °C in 
a humidified incubator containing 5% (v/v) CO2 was carried out for 48 hours before stimulation with IL-33 or 
vehicle for the requisite time. Following cytokine stimulation, RNA or protein was isolated as required.
Statistical analysis. The data are presented as mean ± SEM with normality determined using the 
Shapiro-Wilk test. Single comparisons were performed using an unpaired Student’s t test, or if the data were not 
normally distributed using a Mann Whitney U test. The results were regarded as significant where *p ≤ 0.05, 
**p ≤ 0.01 and ***p ≤ 0.001.
Data Availability
The datasets produced and/or analyzed during this study are available from the corresponding author on reason-
able request.
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